Fig. 2: Prevalence of Helicobacter pylori clarithromycin resistance in adults by age group (relative to the total cohort). | Nature Communications

Fig. 2: Prevalence of Helicobacter pylori clarithromycin resistance in adults by age group (relative to the total cohort).

From: Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides

Fig. 2

a Cla-resistance was diagnosed in 530 cases out of the 2675 adult female patients. Treatment-related subcohorts (resistant cases after eradication failure/eradication-naive resistant cases/macrolide-naive resistant cases) according to age groups: 20–29 years: 4/17/7, 30–39 years: 12/34/12, 40–49 years: 45/45/12, 50–59 years: 53/77/18, 60–69 years: 33/69/12, 70+ years: 24/34/22. b Cla-resistance was diagnosed in 272 cases out of the 2017 adult male patients. Treatment-related subcohorts (resistant cases after eradication failure/eradication-naive resistant cases/macrolide-naive resistant cases) according to age groups: 20–29 years: 1/11/4, 30–39 years: 9/21/10, 40–49 years: 15/20/7, 50–59 years: 19/29/12, 60–69 years: 19/38/8, 70+ years: 9/25/15. Deep blue: macrolide-naive resistant, green: clarithromycin-containing eradication-naive (but other macrolide treatment exposed) resistant, light blue: resistant with a history of Helicobacter pylori eradication with a clarithromycin-containing treatment regimen. Cla: clarithromycin.

Back to article page